{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T09:16:07Z","timestamp":1774084567191,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2001,2,1]],"date-time":"2001-02-01T00:00:00Z","timestamp":980985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":6900,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2001,2]]},"DOI":"10.1023\/a:1008382516636","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T14:41:38Z","timestamp":1040568098000},"page":"259-266","source":"Crossref","is-referenced-by-count":296,"title":["Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse"],"prefix":"10.1016","volume":"12","author":[{"given":"M.","family":"Brada","sequence":"first","affiliation":[]},{"given":"K.","family":"Hoang-Xuan","sequence":"additional","affiliation":[]},{"given":"R.","family":"Rampling","sequence":"additional","affiliation":[]},{"given":"P.-Y.","family":"Dietrich","sequence":"additional","affiliation":[]},{"given":"L.Y.","family":"Dirix","sequence":"additional","affiliation":[]},{"given":"D.","family":"Macdonald","sequence":"additional","affiliation":[]},{"given":"J.J.","family":"Heimans","sequence":"additional","affiliation":[]},{"given":"B.A.","family":"Zonnenberg","sequence":"additional","affiliation":[]},{"given":"J.M.","family":"Bravo-Marques","sequence":"additional","affiliation":[]},{"given":"R.","family":"Henriksson","sequence":"additional","affiliation":[]},{"given":"R.","family":"Stupp","sequence":"additional","affiliation":[]},{"given":"N.","family":"Yue","sequence":"additional","affiliation":[]},{"given":"J.","family":"Bruner","sequence":"additional","affiliation":[]},{"given":"M.","family":"Dugan","sequence":"additional","affiliation":[]},{"given":"S.","family":"Rao","sequence":"additional","affiliation":[]},{"given":"S.","family":"Zaknoen","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"2B","key":"10.1023\/A:1008382516636_bb0010","first-page":"1303","article-title":"Treatment of recurrent high grade astrocytoma: Results of a systematic review of 1415 patients","volume":"18","author":"Huncharek","year":"1998","journal-title":"Anticancer Res"},{"issue":"2","key":"10.1023\/A:1008382516636_bb0015","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF00172671","article-title":"Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure","volume":"12","author":"Spence","year":"1992","journal-title":"J Neurooncol"},{"key":"10.1023\/A:1008382516636_bb0020","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF01051050","article-title":"A phase II study of intravenous carboplatin for the treatment of recurrent gliomas","volume":"19","author":"Warnick","year":"1994","journal-title":"J Neurooncol"},{"issue":"2","key":"10.1023\/A:1008382516636_bb0025","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/BF00146875","article-title":"Treatment of recurrent malignant supratentorial gliomas with carboplatin (CBDCA)","volume":"10","author":"Poisson","year":"1991","journal-title":"J Neurooncol"},{"key":"10.1023\/A:1008382516636_bb0030","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1002\/1097-0142(19891215)64:12<2420::AID-CNCR2820641204>3.0.CO;2-B","article-title":"Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors","volume":"64","author":"Rodriguez","year":"1989","journal-title":"Cancer"},{"key":"10.1023\/A:1008382516636_bb0035","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1212\/WNL.40.11.1743","article-title":"Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure","volume":"40","author":"Newton","year":"1990","journal-title":"Neurology"},{"issue":"4","key":"10.1023\/A:1008382516636_bb0040","first-page":"619","article-title":"Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen","volume":"2","author":"Couldwell","year":"1996","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1023\/A:1008382516636_bb0045","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1200\/JCO.1999.17.2.645","article-title":"Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: A phase II study","volume":"17","author":"Brandes","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008382516636_bb0050","first-page":"A292","article-title":"Fotemustine (F) and cisplatin (P) association in patients with recurrent malignant glioma","volume":"15","author":"Rodier","year":"1996","journal-title":"Proc ASCO"},{"issue":"2","key":"10.1023\/A:1008382516636_bb0055","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1023\/A:1005952925378","article-title":"Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine \u2013 a phase II study","volume":"37","author":"Hildebrand","year":"1998","journal-title":"J Neurooncol"},{"issue":"10","key":"10.1023\/A:1008382516636_bb0060","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/S0959-8049(98)00138-5","article-title":"Phase II study on cisplatin and ifosfamide in recurrent high grade gliomas","volume":"34","author":"van den Bent","year":"1998","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1023\/A:1008382516636_bb0065","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1200\/JCO.1998.16.9.2953","article-title":"Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma North Central Cancer Treatment Group results","volume":"16","author":"Galanis","year":"1998","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1023\/A:1008382516636_bb0070","first-page":"921","article-title":"Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas","volume":"39","author":"Kyritsis","year":"1996","journal-title":"Neurosurgery"},{"issue":"5","key":"10.1023\/A:1008382516636_bb0075","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1023\/A:1008382516636_bb0080","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1023\/A:1005790632126","article-title":"Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma","volume":"34","author":"Osoba","year":"1997","journal-title":"J Neurooncol"},{"issue":"6","key":"10.1023\/A:1008382516636_bb0085","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/BF02994094","article-title":"Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity","volume":"26","author":"Tsang","year":"1990","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1023\/A:1008382516636_bb0090","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/bjc.1996.85","article-title":"Potentiation of temozolomide and BCNU cytotoxicity by 0-6-benzylguanine: A comparative study in vitro","volume":"73","author":"Wedge","year":"1996","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1023\/A:1008382516636_bb0095","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/sj.bjc.6690802","article-title":"Phase I dose-escae (SCH 52365) for refractory or relapsing malignancies","volume":"81","author":"Brada","year":"1999","journal-title":"Br J Cancer"},{"issue":"13","key":"10.1023\/A:1008382516636_bb0100","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1016\/S0959-8049(96)00258-4","article-title":"The Charing Cross Hospital experience with temozolomide in patients with gliomas","volume":"32A","author":"Newlands","year":"1996","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1023\/A:1008382516636_bb0105","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/BF02796204","article-title":"Phase II study of temozolomide in patients with relapsing high grade glioma and poor performance status","volume":"17","author":"Janinis","year":"2000","journal-title":"Med Oncol"},{"issue":"5","key":"10.1023\/A:1008382516636_bb0110","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1054\/bjoc.2000.1316","article-title":"A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse","volume":"83","author":"Yung","year":"2000","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1023\/A:1008382516636_bb0115","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1200\/JCO.1999.17.9.2762","article-title":"Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse","volume":"17","author":"Yung","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008382516636_bb0120","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/1097-0142(19830801)52:3<550::AID-CNCR2820520327>3.0.CO;2-C","article-title":"Necrosis as a prognostic criterion in malignant supratentorial, astrocytic gliomas","volume":"52","author":"Nelson","year":"1983","journal-title":"Cancer"},{"issue":"5","key":"10.1023\/A:1008382516636_bb0125","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/1097-0142(19850901)56:5<1106::AID-CNCR2820560525>3.0.CO;2-2","article-title":"Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications","volume":"56","author":"Burger","year":"1985","journal-title":"Cancer"},{"issue":"7","key":"10.1023\/A:1008382516636_bb0130","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","article-title":"Response criteria for phase II studies of supratentorial malignant glioma","volume":"8","author":"Macdonald","year":"1990","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1023\/A:1008382516636_bb0135","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0895-4356(96)00428-3","article-title":"Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement","volume":"50","author":"Groenvold","year":"1997","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"10.1023\/A:1008382516636_bb0140","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1200\/JCO.2000.18.7.1481","article-title":"Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme","volume":"18","author":"Osoba","year":"2000","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1023\/A:1008382516636_bb0145","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0959-8049(05)80198-4","article-title":"Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours","volume":"29A","author":"O\u2019Reilly","year":"1993","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1023\/A:1008382516636_bb0150","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/sj.bjc.6690802","article-title":"Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies","volume":"81","author":"Brada","year":"1999","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1023\/A:1008382516636_bb0155","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s002800050691","article-title":"Multicenter CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma","volume":"40","author":"Bower","year":"1997","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3, Suppl 6","key":"10.1023\/A:1008382516636_bb0160","first-page":"11","article-title":"Clinical trial end points in malignant glioma: Need for effective trial design strategy","volume":"27","author":"Brada","year":"2000","journal-title":"Semin Oncol"},{"issue":"6","key":"10.1023\/A:1008382516636_bb0165","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1023\/A:1008267312782","article-title":"Malignant glioma: Should chemotherapy be overthrown by experimental treatments?","volume":"9","author":"Hosli","year":"1998","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1023\/A:1008382516636_bb0170","first-page":"537","article-title":"Chemotherapy for brain tumors","volume":"12","author":"Pech","year":"1998","journal-title":"Oncology"},{"issue":"4","key":"10.1023\/A:1008382516636_bb0175","first-page":"297","article-title":"Nitrosoureas: A reappraisal of clinical trials","volume":"2","author":"Katz","year":"1979","journal-title":"Cancer Clin Trials"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419472967?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419472967?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/12\/2\/259\/19479293\/12-2-259.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T06:57:28Z","timestamp":1582181848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419472967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,2]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2001,2]]}},"alternative-id":["S0923753419472967"],"URL":"https:\/\/doi.org\/10.1023\/a:1008382516636","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2001,2]]}}}